1
|
Grunewald TGP, Ranft A, Esposito I, da Silva-Buttkus P, Aichler M, Baumhoer D, Schaefer KL, Ottaviano L, Poremba C, Jundt G, Jürgens H, Dirksen U, Richter GHS, Burdach S. High STEAP1 expression is associated with improved outcome of Ewing's sarcoma patients. Ann Oncol 2012; 23:2185-2190. [PMID: 22317770 DOI: 10.1093/annonc/mdr605] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Ewing's sarcoma (ES) is the second most common bone or soft-tissue sarcoma in childhood and adolescence and features a high propensity to metastasize. The six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is a membrane-bound mesenchymal stem cell marker highly expressed in ES. Here, we investigated the role of STEAP1 as an immunohistological marker for outcome prediction in patients with ES. PATIENTS AND METHODS Membranous STEAP1 immunoreactivity was analyzed using immunohistochemistry in 114 primary pre-chemotherapy ES of patients diagnosed from 1983 to 2010 and compared with clinical parameters and patient outcome. Median follow-up was 3.85 years (range 0.43-17.51). RESULTS A total of 62.3% of the ES samples displayed detectable STEAP1 expression with predominant localization of the protein at the plasma membrane. High membranous STEAP1 immunoreactivity was found in 53.5%, which correlated with better overall survival (P=0.021). Accordingly, no or low membranous STEAP1 expression was identified as an independent risk factor in multivariate analysis (hazard ratio 2.65, P=0.036). CONCLUSION High membranous STEAP1 expression predicts improved outcome and may help to define a specific subgroup of ES patients, who might benefit from adapted therapy regimens.
Collapse
Affiliation(s)
- T G P Grunewald
- Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Laboratory of Functional Genomics and Transplantation Biology, Klinikum rechts der Isar, Technische Universität München, Munich; Medical Life Science and Technology Center, TUM Graduate School, Technische Universität München, Garching.
| | - A Ranft
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster
| | - I Esposito
- Institute of Pathology, Klinikum rechts der Isar, Technische Universität München, Munich; Institute of Pathology, Helmholtz-Zentrum München, Neuherberg, Germany
| | | | - M Aichler
- Institute of Pathology, Helmholtz-Zentrum München, Neuherberg, Germany
| | - D Baumhoer
- Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - K L Schaefer
- Institute of Pathology, Heinrich-Heine-University, Düsseldorf
| | - L Ottaviano
- Institute of Pathology, Heinrich-Heine-University, Düsseldorf
| | - C Poremba
- Institute of Pathology, Heinrich-Heine-University, Düsseldorf; Center of Histopathology, Cytology, and Molecular Diagnostics (CHCMD), Trier, Germany
| | - G Jundt
- Bone Tumor Reference Center at the Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - H Jürgens
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster
| | - U Dirksen
- Department of Pediatric Hematology and Oncology, University Hospital Münster, Münster
| | - G H S Richter
- Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Laboratory of Functional Genomics and Transplantation Biology, Klinikum rechts der Isar, Technische Universität München, Munich
| | - S Burdach
- Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Laboratory of Functional Genomics and Transplantation Biology, Klinikum rechts der Isar, Technische Universität München, Munich
| |
Collapse
|
2
|
Thiel U, Wolf P, Wawer A, Blaeschke F, Grunewald TGP, von Lüttichau IT, Klingebiel T, Bader P, Borkhardt A, Laws HJ, Handgretinger R, Lang P, Schlegel PG, Eyrich M, Gruhn B, Ehninger G, Koscielniak E, Klein C, Sykora KW, Holler E, Mauz-Körholz C, Woessmann W, Richter GHS, Schmidt AH, Peters C, Dirksen U, Jürgens H, Bregni M, Burdach S. Human leukocyte antigen distribution in German Caucasians with advanced Ewing's sarcoma. Klin Padiatr 2012; 224:353-8. [PMID: 22821288 DOI: 10.1055/s-0032-1321730] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
BACKGROUND Risk stratification criteria for patients with Ewing's sarcoma family of tumors (ESFT) are still limited. We hypothesized divergent human leukocyte antigen (HLA) patterns in ESFT patients and compared HLA-A, -B and -DR phenotype frequencies of patients with advanced ESFT with those of healthy controls. PATIENTS HLA types of all German Caucasian patients with advanced ESFT and available HLA-A, -B and -DR data registered in the European Group for Blood and Marrow Transplantation, Paediatric Registry for Stem Cell Transplantation and the MetaEICESS data bases (study group, n=30) were retrospectively compared with HLA types of healthy German stem cell donors (control group, n=8 862 for single HLA frequencies and n=8 839 for allele combinations). Study group patients had been immuno-typed due to eligibility for allogeneic stem cell transplantation for high risk of treatment failure, and thus constituted a selected subgroup of ESFT patients. RESULTS After Bonferroni correction for multiple testing (PC), phenotype frequencies of HLA-A24 remained significantly higher in the study group compared to controls (PC<0.05). Furthermore, several HLA combinations were significantly more frequent in the study group compared to controls (all PC<0.05). CONCLUSION We report an increased incidence of circumscribed HLA patterns in German Caucasians with advanced ESFT. The possible clinical significance of this observation has to be re-assessed in prospective trials comprising larger ESFT patient numbers of all risk groups.
Collapse
Affiliation(s)
- U Thiel
- Department of Pediatrics and Pediatric Oncology Center, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Grunewald TGP, Greulich N, Kontny U, Frühwald M, Rutkowski S, Kordes U, Scheurlen W, Schmidt W, Stachel D, Metzler M, Mittler U, Graf N, Benesch M, Burdach S. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr 2012; 224:124-31. [PMID: 22522984 DOI: 10.1055/s-0032-1301930] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Although prognosis of children with solid tumors is steadily improving, long-term survival is not achievable in all patients, especially in patients with recurrent or refractory disease. Despite the increasing number of targeted therapeutics (TT), only very few TT have been introduced into clinical protocols. Accordingly, clinical experience concerning the efficacy and safety of these drugs is limited. This may possibly discourage oncologists from administering TT to children.We performed a comprehensive review of the literature to identify TT that may be considered for treatment of children and young adults with solid tumors. Moreover, we interviewed an expert panel of the Society for Pediatric Oncology and Hematology (GPOH) using questionnaires in a modified Delphi process in order to describe the experts' experiences in the use of these TT.Among 30 TT identified to be possibly useful in children and young adults, imatinib, bevacizumab and rapamycin were most widely used. These drugs were reported as having mostly little to no severe adverse events and seem to induce at least partial responses in a subset of patients. In addition, our study confirms and expands the present knowledge about adverse events and the potential efficacy of 5 other commonly used TT in this population.This information may be useful for oncologists when administering these TT to children and young adults with solid tumors. Controlled clinical trials are urgently needed to test their safety and efficacy.
Collapse
Affiliation(s)
- T G P Grunewald
- Department of Pediatrics, Children's Cancer Research and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, TU München, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Grunewald TGP, Damke L, Maschan M, Petrova U, Surianinova O, Esipenko A, Konovalov D, Behrends U, Schiessl J, Wörtler K, Burdach S, von Luettichau I. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol 2010; 21:1733-1734. [PMID: 20605931 DOI: 10.1093/annonc/mdq331] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- T G P Grunewald
- Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München; Laboratory of Functional Genomics and Transplantation Biology, Children's Cancer Research Center, Paediatric Oncology and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - L Damke
- Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München
| | - M Maschan
- Department of Haematology, Federal Clinical Research Center for Paediatric Haematology, Oncology and Immunology, Moscow
| | - U Petrova
- Department of Haematology-1, Russian Children's Clinical Hospital, Moscow
| | - O Surianinova
- Department of Haematology, Yaroslavl Regional Children's Hospital, Yaroslavl
| | - A Esipenko
- Department of Haematology, Yaroslavl Regional Children's Hospital, Yaroslavl
| | - D Konovalov
- Department of Pathology, Federal Clinical Research Center for Paediatric Haematology, Oncology and Immunology, Moscow, Russian Federation
| | - U Behrends
- Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München
| | - J Schiessl
- Department of Pathology, Klinikum Schwabing
| | - K Wörtler
- Department of Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - S Burdach
- Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München; Laboratory of Functional Genomics and Transplantation Biology, Children's Cancer Research Center, Paediatric Oncology and Roman Herzog Comprehensive Cancer Center, Klinikum rechts der Isar, Technische Universität München, Munich, Germany
| | - I von Luettichau
- Department of Paediatrics, Klinikum rechts der Isar, Technische Universität München.
| |
Collapse
|
5
|
Grunewald TGP, Kammerer U, Winkler C, Schindler D, Sickmann A, Honig A, Butt E. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 2007; 96:296-305. [PMID: 17211471 PMCID: PMC2359999 DOI: 10.1038/sj.bjc.6603545] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
LIM and SH3 protein 1 (LASP-1), initially identified from human breast cancer, is a specific focal adhesion protein involved in cell proliferation and migration. In the present work, we analysed the effect of LASP-1 on biology and function of human ovarian cancer cell line SKOV-3 using small interfering RNA technique (siRNA). Transfection with LASP-1-specific siRNA resulted in a reduced protein level of LASP-1 in SKOV-3 cells. The siRNA-treated cells were arrested in G(2)/M phase of the cell cycle and proliferation of the tumour cells was suppressed by 60-90% corresponding to around 70% of the cells being transfected successfully as seen by immunofluorescence. Moreover, transfected tumour cells showed a 40% reduced migration. LASP-1 silencing is accompanied by a reduced binding of the LASP-1-binding partner zyxin to focal contacts without changes in actin stress fibre and microtubule organisation or focal adhesion morphology as observed by immunofluorescence. In contrast, silencing of zyxin is not influencing cell migration and had neither influence on LASP-1 expression nor actin cytoskeleton and focal contact morphology suggesting that LASP-1 is necessary and sufficient for recruiting zyxin to focal contacts. The data provide evidence for an essential role of LASP-1 in tumour cell growth and migration, possibly through influencing zyxin localization.
Collapse
Affiliation(s)
- T G P Grunewald
- Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Grombuehlstr. 12, D-97080 Wurzburg, Germany
| | - U Kammerer
- Department of Obstetrics and Gynecology, University of Wurzburg, Josef-Schneider-Str. 4, D-97080 Wurzburg, Germany
| | - C Winkler
- Protein Mass Spectrometry and Functional Proteomics Group, Rudolf-Virchow-Center for Experimental Biomedicine, Versbacher Straße 9, 97078 Wurzburg, Germany
| | - D Schindler
- Department of Human Genetics, University of Wurzburg, Biozentrum am Hubland, D-97074 Wurzburg, Germany
| | - A Sickmann
- Protein Mass Spectrometry and Functional Proteomics Group, Rudolf-Virchow-Center for Experimental Biomedicine, Versbacher Straße 9, 97078 Wurzburg, Germany
| | - A Honig
- Department of Obstetrics and Gynecology, University of Wurzburg, Josef-Schneider-Str. 4, D-97080 Wurzburg, Germany
| | - E Butt
- Institute of Clinical Biochemistry and Pathobiochemistry, University of Wurzburg, Grombuehlstr. 12, D-97080 Wurzburg, Germany
- E-mail:
| |
Collapse
|